60 Degrees Pharmaceuticals Inc. (SXTP)
(Delayed Data from NSDQ)
$0.23 USD
+0.01 (5.17%)
Updated May 9, 2024 03:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SXTP 0.23 +0.01(5.17%)
Will SXTP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SXTP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SXTP
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
60 Degrees Pharmaceuticals outlines upcoming trial of Tafenoquine
60 Degrees Pharmaceuticals, Inc. (SXTP) Receives a Hold from H.C. Wainwright
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
60 Degrees receives FDA comments on Tafenoquine-Babesiosis trial protocol